E. Mizuta

450 total citations
16 papers, 371 citations indexed

About

E. Mizuta is a scholar working on Neurology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, E. Mizuta has authored 16 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 3 papers in Organic Chemistry and 2 papers in Cellular and Molecular Neuroscience. Recurrent topics in E. Mizuta's work include Parkinson's Disease Mechanisms and Treatments (10 papers), Botulinum Toxin and Related Neurological Disorders (3 papers) and Neurological disorders and treatments (2 papers). E. Mizuta is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (10 papers), Botulinum Toxin and Related Neurological Disorders (3 papers) and Neurological disorders and treatments (2 papers). E. Mizuta collaborates with scholars based in Japan. E. Mizuta's co-authors include Sadako Kuno, Naoki Yoshimura, O Yoshida, Masashi Sasa, Kenji Yamamoto, Shun Shimohama, Hideyuki Sawada, Tomoko Oeda, Katsutoshi Yamakawa and Ryosuke Takahashi and has published in prestigious journals such as Diabetes, Journal of Pharmacology and Experimental Therapeutics and Tetrahedron.

In The Last Decade

E. Mizuta

14 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Mizuta Japan	8	201	132	119	52	38	16	371
H. Schr�der Denmark	10	17 0.1×	108 0.8×	82 0.7×	9 0.2×	119 3.1×	16	469
David Cunnah United Kingdom	11	30 0.1×	62 0.5×	12 0.1×	23 0.4×	94 2.5×	12	522
K. Roger Aoki United States	4	196 1.0×	58 0.4×	15 0.1×	4 0.1×	24 0.6×	6	385
Stephanie Hauge United States	6	11 0.1×	113 0.9×	42 0.4×	13 0.3×	64 1.7×	8	278
Yuichi Satoh Japan	11	109 0.5×	50 0.4×	9 0.1×	28 0.5×	43 1.1×	30	400
Robert J. Theobald United States	11	6 0.0×	64 0.5×	239 2.0×	37 0.7×	61 1.6×	23	372
Rachel Price United States	8	6 0.0×	124 0.9×	209 1.8×	53 1.0×	174 4.6×	11	430
Mara Astolfi Italy	10	10 0.0×	280 2.1×	54 0.5×	11 0.2×	209 5.5×	14	395
Kwo Wei David Ho United States	12	192 1.0×	124 0.9×	3 0.0×	8 0.2×	46 1.2×	31	419
L. I. Wallis United Kingdom	9	220 1.1×	84 0.6×	2 0.0×	21 0.4×	67 1.8×	13	410

Countries citing papers authored by E. Mizuta

Since Specialization

Citations

This map shows the geographic impact of E. Mizuta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Mizuta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Mizuta more than expected).

Fields of papers citing papers by E. Mizuta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Mizuta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Mizuta. The network helps show where E. Mizuta may publish in the future.

Co-authorship network of co-authors of E. Mizuta

This figure shows the co-authorship network connecting the top 25 collaborators of E. Mizuta. A scholar is included among the top collaborators of E. Mizuta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Mizuta. E. Mizuta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Horikoshi, Yosuke, et al.. (2024). 614-P: Effects of Umami Stimulation on Oral Environment of Type 2 Diabetes Mellitus Patients. Diabetes. 73(Supplement_1).

Sawada, Hideyuki, Tomoko Oeda, Kenji Yamamoto, et al.. (2008). Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. European Journal of Neurology. 16(2). 174–182. 73 indexed citations

Sawada, Hirohide, et al.. (2007). 1.178 Risk factors for psychosis in Parkinson disease. Parkinsonism & Related Disorders. 13. S53–S54. 1 indexed citations

Kuno, Sadako, et al.. (1998). Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.. PubMed. 21(1). 35–40. 1 indexed citations

Yoshimura, Naoki, E. Mizuta, O Yoshida, & Sadako Kuno. (1998). Therapeutic Effects of Dopamine D1/D2Receptor Agonists on Detrusor Hyperreflexia in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Parkinsonian Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics. 286(1). 228–233. 92 indexed citations

Kuno, Sadako, et al.. (1997). 3-30-17 Combined effects of long-acting D2 agonist, cabergoline and L-DOPA on parkinsonism in MPTP-treated cynomolgus monkeys. Journal of the Neurological Sciences. 150. S182–S182.

Isaji, Masayuki, et al.. (1996). Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys. Journal of Neural Transmission. 103(11). 1307–1316. 16 indexed citations

Isaji, Masayuki, et al.. (1995). Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. Journal of Neural Transmission - Parkinsons Disease and Dementia Section. 10(1). 55–62. 19 indexed citations

Ozawa, M., et al.. (1995). Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.. Journal of Pharmacology and Experimental Therapeutics. 273(1). 309–314. 22 indexed citations

10.

Mizuta, E. & Sadako Kuno. (1993). Rotations induced by L-dopa in parkinsonian rats are reduced by an ingestion of amino acids. Journal of Neural Transmission - Parkinsons Disease and Dementia Section. 6(3). 211–214. 2 indexed citations

11.

Yoshimura, Naoki, E. Mizuta, Sadako Kuno, Masashi Sasa, & O Yoshida. (1993). The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology. 32(4). 315–321. 95 indexed citations

12.

Inooka, Hiroshi, Satoshi Endo, Chieko Kitada, E. Mizuta, & Yoshihisa Fujino. (1992). Pituitary adenylate cyclase activating polypeptide (PACAP) with 27 residues. Conformation determined by 1H NMR and CD spectroscopies and distance geometry in 25% methanol solution.. PubMed. 40(5). 456–64. 24 indexed citations

13.

Fujitake, Junko, Sadako Kuno, & E. Mizuta. (1990). Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.. PubMed. 53. 225–9. 1 indexed citations

14.

Mizuta, E., et al.. (1982). [The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea].. PubMed. 35(12). 2879–93. 1 indexed citations

15.

Mizuta, E., et al.. (1973). Simulation of blood level of drugs by digital computer. 32(4). 522–531. 4 indexed citations

16.

Ochiai, Masahito, E. Mizuta, Yutaka Asahi, & Katsura Morita. (1968). A novel photo-induced methylation of pyrimidines and condensed pyrimidines. Tetrahedron. 24(17). 5861–5870. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact